论文部分内容阅读
目的评价熊去氧胆酸治疗戊型病毒性肝炎肝内胆汁淤积症的疗效和安全性。方法将38例戊肝肝内胆汁淤积症患者随机分为两组,治疗组20例,对照组18例,治疗组在常规药物治疗的基础上加用熊去氧胆酸,疗程为4周。观察两组治疗前后血清总胆红素(TBIL)、总胆汁酸(TBA)、谷丙转氨酶(AIT)、碱性磷酸酶(ALP)、y-谷氨酰基转移酶(GGT),同时观察患者的症状和体征的变化。结果治疗组总有效率高于对照组,TBIL、TBA、ALP、GGT水平与对照组相比显著降低,而ALT水平与对照组相比,差异无显著性,所有观察病例无严重不良反应发生。结论熊去氧胆酸治疗戊型肝炎肝内胆汁淤积症有效、安全。
Objective To evaluate the efficacy and safety of ursodeoxycholic acid in the treatment of intrahepatic cholestasis of type-V viral hepatitis. Methods Thirty-eight patients with intrahepatic cholestasia of hepatitis E were randomly divided into two groups, 20 cases in the treatment group and 18 cases in the control group. The treatment group was given ursodeoxycholic acid on the basis of conventional drug treatment for 4 weeks. The levels of total bilirubin (TBIL), total bile acid (TBA), alanine aminotransferase (AIT), alkaline phosphatase (ALP) and γ-glutamyltransferase (GGT) in both groups were observed before and after treatment. Symptoms and signs of change. Results The total effective rate in the treatment group was higher than that in the control group. The levels of TBIL, TBA, ALP and GGT in the treatment group were significantly lower than those in the control group. There was no significant difference in ALT levels between the two groups. No adverse reactions were observed in all the cases. Conclusion Ursodeoxycholic acid treatment of hepatitis E intrahepatic cholestasis effective and safe.